Phase 1 Solid Tumor trials recruiting now

All Solid Tumor trials, every phase

Other phases for Solid Tumor

Phase 1 Solid Tumor trials

• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  NCT06616766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
  NCT06403735 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
  NCT06245330 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
  NCT03829254 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
  NCT05470348 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
  NCT06493864 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
  NCT07056556 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
  NCT06500052 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
  NCT06503783 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
  NCT07232420 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of GC203 TIL in Advanced Malignant Solid Tumors
  NCT06375187 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
  NCT06609187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
  NCT06612840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
  NCT05859074 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
  NCT07300150 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · 16 locations
• A Study of TRK-950 in Patients With Advanced Solid Tumors
  NCT05423262 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
  NCT04300556 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 116 locations
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
  NCT07094204 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
  NCT03740256 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Brodalumab in the Treatment of Immune-Related Adverse Events
  NCT06673329 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  NCT07517198 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
  NCT06669117 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Imaging of Solid Tumors Using 18F-TRX
  NCT06942104 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Indocyanine Green (ICG) Guided Tumor Resection
  NCT04084067 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
  NCT04952272 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
  NCT05076760 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
  NCT05381038 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 99 Years · Sex: All (male and female) · 1 location
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
  NCT05245500 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
  NCT05544240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
  NCT07151040 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  NCT05786924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
  NCT06171750 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
  NCT06307249 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
  NCT06398418 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• RAPA-201 Therapy of Solid Tumors
  NCT05144698 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SMP-3124LP in Adults With Advanced Solid Tumors
  NCT06526819 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
  NCT06810544 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
  NCT07589205 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
  NCT04930432 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 87 locations
• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
  NCT07165132 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
  NCT04900818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
  NCT05784688 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 244 locations
• Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
  NCT07358806 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.